Myles Smith
YOU?
Author Swipe
View article: Management of peripheral-vein leiomyosarcomas, recurrence patterns and individualised treatment strategy
Management of peripheral-vein leiomyosarcomas, recurrence patterns and individualised treatment strategy Open
Peripheral vein LMS demonstrates a low local recurrence but high metastatic risk. Radiotherapy did not significantly impact local control, and it was typically utilized in higher-grade, deep-seated tumours that carry a greater risk of loca…
View article: Melanoma: assessment and management summary of the 2022 update of the National Institute for Health and Care Excellence guidelines
Melanoma: assessment and management summary of the 2022 update of the National Institute for Health and Care Excellence guidelines Open
Melanoma is the fifth most common cancer in the UK, accounting for 4% of all new cases of cancer, with a predicted 7% increase in incidence between 2014 and 2035. In parallel, since the initial publication of the National Institute for Hea…
View article: Ossifying fibromyxoid tumours: A case series
Ossifying fibromyxoid tumours: A case series Open
Given the limited clinical experience with OFMT, multidisciplinary tumour boards are crucial for tailoring individualized treatment strategies. This study contributes to the growing body of literature on OFMT, providing a foundation for fu…
View article: Robotic MRI/CT Guided Multiregional ‘smart’ Biopsy for Characterization of Tumor Heterogeneity: A Prospective Development Study
Robotic MRI/CT Guided Multiregional ‘smart’ Biopsy for Characterization of Tumor Heterogeneity: A Prospective Development Study Open
Multiregional robotic MRI-informed, CT-guided biopsy is feasible and safe in RPS. Sampling three distinct regions within tumors provides a more comprehensive and accurate representation of tumor biology than standard biopsy. The close rela…
View article: Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines
Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines Open
Background British Sarcoma Group guidelines for the management of GIST were initially informed by those published by the European Society of Clinical Oncology. This update was written by a group of experts to includes a discussion of the h…
View article: Primary pelvic soft tissue sarcomas (PELVISARC): outcomes from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)
Primary pelvic soft tissue sarcomas (PELVISARC): outcomes from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Open
International audience
View article: Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors
Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors Open
This study aims to review the status of the clinical use of monoclonal antibodies (mAbs) that have completed or are in ongoing clinical trials for targeted fluorescence-guided surgery (T-FGS) for the intraoperative identification of the tu…
View article: Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study
Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study Open
Ripretinib, a novel tyrosine kinase inhibitor used in advanced gastrointestinal stromal tumors (GIST) resistant to standard therapies, was assessed in the United Kingdom (UK) within an Expanded Access Program (EAP). A retrospective review …
View article: Supplementary Materials and Methods from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Supplementary Materials and Methods from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer Open
Supplementary Materials and Methods (unmarked)
View article: Supplementary Materials and Methods from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Supplementary Materials and Methods from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer Open
Supplementary Materials and Methods (unmarked)
View article: Tables S2-S5 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Tables S2-S5 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer Open
Supplementary Table S2. Sphere-initiating frequency in hypoxia as measured by LDA in vitro, related to Figure 1C. Supplementary Table S3. C-IC frequency following hypoxia as measured by LDA in vivo, related to Figure 1D. Supplementary Tabl…
View article: Table S1 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Table S1 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer Open
Supplementary Table S1. Summary of colorectal cancer patient samples used in this study. The tissue site from which samples originated or were collected, disease stage, and main driver mutations are listed.
View article: Figure S1-S6 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Figure S1-S6 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer Open
Supplementary Figure S1. Hypoxia increases stem gene expression and stabilizes HIF proteins. Supplementary Figure S2. Chemotherapy enriches for colorectal C-IC markers and increases expression of Wnt and HIF targets. Supplementary Figure S…
View article: Table S1 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Table S1 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer Open
Supplementary Table S1. Summary of colorectal cancer patient samples used in this study. The tissue site from which samples originated or were collected, disease stage, and main driver mutations are listed.
View article: Data from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Data from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer Open
Purpose: Cancer-initiating cells (C-IC) have been described in multiple cancer types, including colorectal cancer. C-ICs are defined by their capacity to self-renew, thereby driving tumor growth. C-ICs were initially thought to be static e…
View article: Figure S1-S6 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Figure S1-S6 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer Open
Supplementary Figure S1. Hypoxia increases stem gene expression and stabilizes HIF proteins. Supplementary Figure S2. Chemotherapy enriches for colorectal C-IC markers and increases expression of Wnt and HIF targets. Supplementary Figure S…
View article: Data from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Data from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer Open
Purpose: Cancer-initiating cells (C-IC) have been described in multiple cancer types, including colorectal cancer. C-ICs are defined by their capacity to self-renew, thereby driving tumor growth. C-ICs were initially thought to be static e…
View article: Tables S2-S5 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Tables S2-S5 from Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer Open
Supplementary Table S2. Sphere-initiating frequency in hypoxia as measured by LDA in vitro, related to Figure 1C. Supplementary Table S3. C-IC frequency following hypoxia as measured by LDA in vivo, related to Figure 1D. Supplementary Tabl…
View article: Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval
Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval Open
Over the past 20 years, the management of gastrointestinal stromal tumors has acted as an important model in the advancement of molecularly targeted therapies for solid tumors. The success of imatinib has established it as a lasting therap…